Drug Combination Details
| General Information of the Combination (ID: C27865) | |||||
|---|---|---|---|---|---|
| Name | Beta lapachone NP Info | + | Fluconazole Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Candidosis
[ICD-11: 1F23]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Candida albicans | Microorganism model | Candida albicans | |||
| Experimental
Result(s) |
Beta-lapachone reverted antifungal resistance of S. cerevisiae and C. albicans strains overexpressing CaCdr2p and CaMdr1p transporters by inhibiting these proteins activities. CaCdr2p ATPase activity was not impaired by the compound. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic interactions between Beta-lapachone and fluconazole in the inhibition of CaCdr2p and CaMdr1p in Candida albicans. Rev Iberoam Micol. Jul-Oct 2020;37(3-4):104-106. | |||
